In this study, we have demonstrated consistently, across a range of human and animal models, that ACE2, a receptor facilitating entry of SARS-CoV-2 into the respiratory tract, is upregulated in COPD and suppressed by ICS treatment. Here, ACE2 is linked to chronic obstructive pulmonary disease.